BIO 2026: A Data Driven Perspective of the Largest Pharma Conference

I spent the weekend pulling the raw numbers from the public BIO website to try and gain a more objective perspective of the conference. The registration export, the exhibitor list, the speaker roster, the full session catalog — 9,743 BIO Partnering delegates, more than 1,500 booths, 908 speakers, 443 sessions. I've attached a PDF report with Graphs and Figures to help make sense of things.

Here's what the spending says.

1. A booth and a meeting pass are two different confessions

The first thing to understand is that BIO sells two completely different things, and buying one doesn't mean buying the other. A booth is a marketing spend. It buys visibility on the exhibit floor. A BIO Partnering registration is a dealmaking spend. It buys a seat at the meeting-scheduling system where actual business gets done. Rank places by each and the lists barely overlap, which is the whole game.

California tops both — about 73 exhibitors and close to 800 dealmakers, first by a mile in each. Below that the two diverge fast. Texas buys the second-most booths of any state but doesn't crack the top five for dealmakers. New York and Pennsylvania do the reverse, sending large meeting delegations on relatively modest floor presence. Massachusetts sits second in dealmakers with under 600, well behind its own reputation for booth dominance. If you judged the action by walking the hall, you'd rank these states completely wrong. The booths tell you who wanted to be seen. The meeting passes tell you who came to work.

2. Eli Lilly bought the biggest seat at the table

Some numbers don't need much interpretation. Eli Lilly registered 115 people for BIO Partnering. The next-biggest corporate delegation, Johnson & Johnson, sent 59. After that it falls into the high thirties — Genentech and Roche, Daiichi Sankyo, Novartis. You can find a dozen reasons to buy a large booth, but you don't fly 115 people across the country and pay roughly $3,500 a head for partnering access unless you intend to come home with deals. Lilly didn't come to exhibit. It came to shop.

3. The program the organizers built was about approval and money

The session catalog is where you can hear what BIO itself thinks the industry needs to talk about. Strip out the paid company-pitch slots and you're left with 231 curated sessions. Count what they cover, and the supposed headline of the week comes in third. Regulatory and FDA topics turned up in 53 of them. Investment and capital, another 53. AI and machine learning, 46 — behind both, and behind manufacturing too. China and Asia as a theme appeared 13 times, fewer than rare disease.

AI was genuinely present, with its own dedicated track. But a curated program is a set of choices about what deserves limited stage time, and the people building it spent that time on the two things that actually decide whether a drug reaches a patient: clearing the regulator and finding the money. The hallway chatter and the official agenda were not about the same subject.

4. For an "AI convention," exactly one tech company made the stage

If BIO 2026 were really the AI event everyone described, the people building AI would have been on the main stages. They weren't. Among the most-featured speaking organizations, a single one came from tech: NVIDIA. No OpenAI, no Google, no Microsoft, none of the AI-drug-discovery startups that dominate the press. The rest of the top of the list was pharma, regulators, a couple of trade publications, and one investor. The chipmaker was invited to the front of a very long line of drugmakers — present, but as a supplier to the real business, not the business itself.

5. The regulators out-talked nearly every drug company

Look at who held the microphone and the priorities get even clearer. After the host organization, the two most-featured bodies on stage were the European Medicines Agency, with 22 speaking slots, and the U.S. FDA, with 17. Both spoke more than any individual drug company except Genentech. Pfizer, Lilly, and Johnson & Johnson landed around six apiece. An industry that hands its regulators that much airtime is telling you where its real uncertainty sits. Not in the science, not in foreign competition, but in whether the agencies will say yes.

6. The biggest foreign delegation wasn't China. It was South Korea, then Japan.

Now to the story everyone got backwards. The country that sent the most dealmakers outside the United States was South Korea, with just under 500. Then Japan, with around 470. Then a long drop to the UK and Canada in the high 200s and low 300s.

China sent 193.

For a week whose international conversation was almost entirely about China — the competitive threat, the proposed legislation to block U.S.-China biopharma deals, the question of who's catching up — the country itself was one of the quieter delegations in the building. The two that came in force were South Korea and Japan, and the gap wasn't close.

7. Korea and Japan came to run the exact play China is supposed to be running

This is the part the China panels missed. Korea and Japan are mature pharma economies sitting on Phase 2 and Phase 3 clinical assets they need to push into U.S. commercial channels through licensing and partnership. That is precisely the strategy the industry keeps warning China is about to unleash. Korea and Japan didn't warn about it. They showed up and did it.

Japan's numbers show the behavior in its purest form: roughly 470 dealmakers on only about 34 booths, the lowest booth count in the top ten next to the second-highest delegation. Almost no floor presence, all meetings. And it wasn't one giant company skewing the figure — four of the fifteen largest corporate delegations at the entire convention were Japanese: Daiichi Sankyo, Chugai, Shionogi, and Astellas. A whole national industry came to transact and skipped the marketing.

South Korea backed its delegation with money and the state. Booth space plus partnering fees put its estimated spend at about $2.1M — second only to the host country, ahead of Japan's $1.8M and more than double China's $0.8M. And it isn't new. BIO's own materials ranked South Korea the top international delegation in 2025 as well, and this year Korean government trade bodies ran their own investor-matchmaking events in San Diego alongside the convention. I moderated the opening talk at one of them, KITA's DISCOVER AI × LIFE SCIENCES evening, which put Korean startups in front of Pfizer, AbbVie, NVIDIA, and a room full of U.S. investors. Two years at the top, with government backing and a parallel program built to land deals — that's an industrial strategy, not a coincidence of registrations.

8. Even the venture capital on stage was the dealmaking kind

For an event the recaps cast as a launchpad for the next wave of biotech, the venture presence on the main stages was a single firm: Sofinnova Investments, with eight speaking slots — tied with Sanofi and ahead of most pharma companies. No seed funds, no early-stage names, none of the VCs who write first checks.

Which firm it is matters. Sofinnova is a crossover and late-stage investor. Its model is backing companies that have already proven their science in the clinic and are heading toward commercialization, M&A, and IPOs. It isn't in the business of funding ideas; it's in the business of moving assets that are nearly ready to sell. The one venture name BIO elevated does work that looks less like startup investing and more like the late-stage dealmaking everyone else came for. Even the conference's idea of venture capital is a dealmaker.

9. India bought a big booth to sell services, not assets

India is the cleanest illustration of the whole booth-versus-meeting split. It bought 58 booths, the third-most of any country, behind only Canada and Germany. By floor presence, India looked like a heavyweight. But it sent only 79 dealmakers — short of the top ten, behind France, Switzerland, and Australia.

The gap makes sense once you see who came. Nearly a third of India's delegates worked for contract manufacturers and research organizations, the CMOs and CROs that make and test drugs for hire, against about one in eight across the convention overall. India didn't arrive with a pipeline of late-stage molecules to license. It arrived to win the manufacturing and testing contracts for everyone else's. A booth is the right tool for selling a service; a partnering pass is the right tool for selling an asset. India bought booths.

10. One in eight delegates was there to build the drug, not sell it

India's pattern points at a bigger one. About 1,200 of the convention's delegates — roughly one in eight — came from CMOs and CROs, the service layer that manufactures and tests other companies' drugs. That's a larger contingent than any single foreign country's entire delegation. The supply chain showed up in force, which tells you the dealmaking at BIO isn't only about who owns a molecule. It's also about who's going to make it once the deal closes. You don't bring the factory to the table unless there's something real about to be built.

What it adds up to

Put the spending side by side and the event names itself. The companies that came in force came to buy and sell drugs that already exist. The regulators got the microphone because approval is the gate every one of those deals has to clear. The lone AI company was there because AI is a tool the dealmakers use, not the thing being sold. The lone prominent VC was there because late-stage assets are what venture chases once the early market tightens. And the manufacturers came because a deal is only worth signing if someone can build the product.

Nobody who mattered at BIO 2026 was there to launch a company. They were there to move a Phase 3 asset, clear it through the FDA, and find a partner to commercialize it. That's why the AI-and-China framing missed so badly — those are startup-world and geopolitics-world stories, and this was a room full of people doing late-stage pharma business with each other. The delegations that understood that best, South Korea and Japan, didn't pay to be noticed. They paid to be in the meetings where assets change hands.

The full data set behind this — every chart, plus the complete country and company breakdowns — is in the BIO 2026 Definitive Report below.